Known targets — ChEMBL curated mechanism
GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3B
The experimentally established mechanism targets of Delucemine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.63 |
| ▸ | HRH1 | P35367 | 2/20 | 0.63 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.60 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Delucemine SCHEMBL1661363 | 0.98 | HTR2A (0.61) | HTR2AHRH1SLC6A4SLC6A2TAAR1 | |
| SCHEMBL6900402 | 0.97 | HTR2A (0.70) | HTR2AHRH1SLC6A4SLC6A2TAAR1 | |
| Delucemine SCHEMBL1649904 | 0.97 | HTR2A (0.59) | HTR2AHRH1SLC6A4SLC6A2TAAR1 | |
| SCHEMBL14415637 | 0.88 | SLC6A4 (0.60) | HTR2AHRH1SLC6A4SLC6A2 | |
| SCHEMBL14415664 | 0.87 | SLC6A4 (0.49) | HTR2AHRH1SLC6A4SLC6A2TAAR1 | |
| SCHEMBL14415663 | 0.85 | SLC6A4 (0.50) | HTR2AHRH1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL6050357 | 0.83 | SLC6A4 (0.54) | HTR2AHRH1SLC6A4SLC6A2TAAR1 | |
| SCHEMBL6001268 | 0.83 | CYP19A1 (0.44) | HTR2AHRH1SLC6A4SLC6A2CYP19A1 | |
| SCHEMBL14415703 | 0.82 | CYP19A1 (0.47) | HTR2AHRH1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL2305030 | 0.81 | SLC6A4 (0.55) | HTR2AHRH1SLC6A4SLC6A2TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 274 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12589097-B2 | Apilimod compositions and methods of use | OrphAl Therapeutics Inc. (US) | 2026-03-31 | — | — | US | claimed |
| US-12539337-B2 | Nanostructure conjugates for modulation of location-specific subtypes of receptors and ion channels | Molokanova, Elena (US) | 2026-02-03 | — | — | US | claimed |
| WO-2025264860-A2 | METHODS OF TREATING POST-COVID AIRWAY DISEASE | YALE UNIVERSITY (US) | 2025-12-26 | — | — | WO | claimed |
| EP-4629989-A2 | TREATMENT OR PREVENTION OF DEPRESSIVE DISORDERS THROUGH COMBINATION THERAPY | Freedom Biosciences, Inc. (US) | 2025-10-15 | — | — | EP | claimed |
| EP-4623932-A1 | AGENT FOR ALLEVIATING CLOZAPINE-INDUCED SIALORRHEA | National University Corporation Chiba University (JP) | 2025-10-01 | — | — | EP | claimed |
| US-20250195505-A1 | USE OF DEXTROMETHORPHAN IN COMBINATION WITH CYP2D6 AND CYP3A4 ENZYME INHIBITORS FOR THE TREATMENT OF PAIN | BIOBINA LLC | 2025-06-19 | — | — | US | claimed |
| US-20250161296-A1 | USE OF DEXTROMETHORPHAN IN COMBINATION WITH CYP2D6 AND CYP3A4 ENZYME INHIBITORS FOR THE TREATMENT OF PAIN | BIOBINA LLC | 2025-05-22 | — | — | US | claimed |
| US-12303503-B1 | Use of dextromethorphan in combination with CYP2D6 and CYP3A4 enzyme inhibitors for the treatment of pain | BIOBINA LLC (US) | 2025-05-20 | — | — | US | claimed |
| WO-2025030033-A1 | APILIMOD COMPOSITIONS AND METHODS OF USE | ORPHAI THERAPEUTICS INC. (US) | 2025-02-06 | — | — | WO | claimed |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2025-01-30 | — | — | US | claimed |
| US-11957688-B2 | Combination therapy with apilimod and glutamatergic agents | OrphAl Therapeutics Inc. (US) | 2024-04-16 | — | — | US | claimed |
| US-20240066003-A1 | NEURODEVELOPMENTAL DISORDER THERAPY | ANAVEX LIFE SCIENCES CORP. (US) | 2024-02-29 | — | — | US | claimed |
| US-20240024332-A1 | APILIMOD COMPOSITIONS AND METHODS OF USE | ACADIA WOODS PARTNERS, LLC | 2024-01-25 | — | — | US | claimed |
| US-20230355596-A1 | COMPOSITIONS AND METHODS OF USING NMDAR INHIBITORS AND KINASE INHIBITORS TO TREAT LIVER CANCER | VERSITECH LIMITED (CN) | 2023-11-09 | — | — | US | claimed |
| US-20230069069-A1 | COMBINATION THERAPY WITH APILIMOD AND GLUTAMATERGIC AGENTS | AI Therapeutics, Inc. (US) | 2023-03-02 | — | — | US | claimed |
| US-20220401366-A1 | LONG ACTING NMDA ANTAGONISTS | CONSEGNA PHARMA INC (US) | 2022-12-22 | — | — | US | claimed |
| US-11510929-B2 | Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-11-29 | — | — | US | claimed |
| US-20220354827-A1 | NTRANASAL DANTROLENE ADMINISTRATION FOR TREATMENT OF ALZHEIMER'S DISEASE | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2022-11-10 | — | — | US | claimed |
| US-11439649-B2 | Combination therapy with apilimod and glutamatergic agents | AI Therapeutics, Inc. (US) | 2022-09-13 | — | — | US | claimed |
| CN-114828848-A | Intranasal dantrolene administration for the treatment of alzheimer's disease | 宾夕法尼亚大学理事会 | 2022-07-29 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11510929-B2 | Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids | GABRB2, GABRA4, GABRB1 | HTR2A 713/4885HRH1 1692/4885SLC6A4 525/4885 |
| US-20230355596-A1 | COMPOSITIONS AND METHODS OF USING NMDAR INHIBITORS AND KINASE INHIBITORS TO TREAT LIVER CANCER | GRIN1, GRIN3A, GRIN3B | HTR2A 1047/4885HRH1 2763/4885SLC6A4 902/4885 |
| US-12589097-B2 | Apilimod compositions and methods of use | ZAP70, PIK3R4, PIKFYVE | HTR2A 3549/4885HRH1 3950/4885SLC6A4 1010/4885 |
| US-12539337-B2 | Nanostructure conjugates for modulation of location-specific subtypes of receptors and ion channels | GRIN2B, GRIN2A, GRIN3A | HTR2A 244/4885HRH1 528/4885SLC6A4 115/4885 |
| US-11439649-B2 | Combination therapy with apilimod and glutamatergic agents | GRIK4, GRIN3A, GRIN2A | HTR2A 189/4885HRH1 2862/4885SLC6A4 122/4885 |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | TACR1, ACHE, TACR2 | HTR2A 207/4885HRH1 191/4885SLC6A4 1763/4885 |
| US-11957688-B2 | Combination therapy with apilimod and glutamatergic agents | GRIK4, GRIN3A, GRIN2A | HTR2A 189/4885HRH1 2862/4885SLC6A4 122/4885 |
| US-20240024332-A1 | APILIMOD COMPOSITIONS AND METHODS OF USE | GRIN3A, GRIN2A, GRIK4 | HTR2A 175/4885HRH1 3655/4885SLC6A4 443/4885 |
| US-20230069069-A1 | COMBINATION THERAPY WITH APILIMOD AND GLUTAMATERGIC AGENTS | GRIK4, GRIN3A, GRIN2A | HTR2A 189/4885HRH1 2862/4885SLC6A4 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.